EGFR nuclear translocation modulates DNA repair following cisplatin and ionizing radiation treatment.
Epidermal growth factor receptor (EGFR) overexpression is associated with resistance to chemotherapy and radiotherapy. It modulates DNA repair after radiation-induced damage through association with the catalytic subunit of DNA protein kinase (DNA-PKcs). We investigated the role of EGFR nuclear import and its association with DNA-PKcs on DNA repair after exposure to cisplatin or ionizing radiation (IR). The model system was based on EGFR-null murine NIH3T3 fibroblasts in which EGFR expression was restored with isoforms that were wild-type (wt), derived from human cancers (L858R, EGFRvIII), or mutated in the nuclear localization signal (NLS) sequence. In cells expressing wtEGFR or EGFRvIII, there was complete unhooking of cisplatin-induced interstrand cross-links and repair of IR-induced strand breaks. In contrast, cells expressing L858R or NLS mutations showed reduced unhooking of interstrand cross-links and repair of strand breaks. Immunoprecipitation showed wtEGFR and EGFRvIII binding to DNA-PKcs, increasing 2-fold 18 hours after cisplatin therapy. Confocal microscopy and proximity ligation assay showed that this interaction in the cytoplasm and nucleus was associated with increased DNA protein kinase complex (DNA-PK) activity. Cells expressing the EGFR L858R mutation, which has constitutive kinase activity, exhibited reduced DNA repair without nuclear localization. EGFR-NLS mutants showed impaired nuclear localization and DNA-PKcs association with reduced DNA repair and DNA-PK kinase activity. In summary, EGFR nuclear localization was required for modulation of cisplatin and IR-induced repair of DNA damage. EGFR-DNA-PKcs binding was induced by cisplatin or IR but not by EGFR nuclear translocation per se. Our findings show that EGFR subcellular distribution can modulate DNA repair kinetics, with implications for design of EGFR-targeted combinational therapies.
Cancer Research UK Drug-DNA Interactions Research Group, UCL Cancer Institute, University College London, London, United Kingdom.
Gianmaria
G
Liccardi
John A
JA
Hartley
Daniel
D
Hochhauser
D021581:Active Transport, Cell Nucleus / Q000187:drug effects / Q000528:radiation effects; D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology; D002945:Cisplatin / Q000494:pharmacology*; D004260:DNA Repair; D051747:DNA-Activated Protein Kinase / Q000378:metabolism; D066246:ErbB Receptors / Q000096:biosynthesis / Q000235:genetics / Q000378:metabolism*; D005347:Fibroblasts / Q000187:drug effects / Q000378:metabolism / Q000528:radiation effects; D006801:Humans; D051379:Mice; D041681:NIH 3T3 Cells; D014162:Transfection
D000970:Antineoplastic Agents; C410723:epidermal growth factor receptor VIII; D066246:ErbB Receptors; D051747:DNA-Activated Protein Kinase; D002945:Cisplatin
Oncogene. 2009 Oct 29;28(43):3801-13
19684613
J Clin Oncol. 2003 Jun 15;21(12):2237-46
12748244
Cell. 2000 Oct 13;103(2):211-25
11057895
Mol Cancer Ther. 2009 Nov;8(11):3015-23
19887555
Clin Cancer Res. 1999 Dec;5(12):4164-74
10632356
Clin Cancer Res. 2009 Nov 1;15(21):6484-9
19861462
Am J Transl Res. 2009 Mar 08;1(3):249-58
19956435
Oncogene. 2010 Jul 15;29(28):3997-4006
20473332
Mol Cancer Ther. 2006 Feb;5(2):209-18
16505093
Br J Cancer. 2007;96 Suppl:R16-20
17393580
Cell. 2009 Jun 26;137(7):1293-307
19563760
Mol Carcinog. 2009 Jul;48(7):610-7
19058255
Int J Radiat Biol. 2007 Nov-Dec;83(11-12):781-91
18058366
Nat Rev Cancer. 2006 Nov;6(11):876-85
17036041
Cancer Res. 2007 Jun 1;67(11):5267-74
17545606
Mol Cell Biol. 2005 Sep;25(17):7734-42
16107719
Clin Cancer Res. 2004 Oct 1;10(19):6476-86
15475435
Cancer Res. 2010 Apr 1;70(7):2862-9
20215522
Mol Cancer Res. 2010 Feb;8(2):232-45
20145033
Cancer Res. 2009 May 15;69(10):4252-9
19435898
Expert Opin Biol Ther. 2001 Jul;1(4):719-32
11727507
Nucleic Acids Res. 2003 Oct 1;31(19):5501-12
14500812
Radiother Oncol. 2005 Aug;76(2):157-61
16024112
Mol Biol Cell. 2007 Mar;18(3):1064-72
17215517
J Biol Chem. 2004 Aug 20;279(34):35510-7
15169778
PLoS Comput Biol. 2009 Aug;5(8):e1000487
19714203
Mol Cancer Ther. 2008 Jul;7(7):1772-81
18644989
J Biol Chem. 1998 Jan 16;273(3):1568-73
9430697
J Clin Oncol. 2000 Nov 1;18(21 Suppl):47S-53S
11060327
Exp Cell Res. 2008 Jan 15;314(2):413-9
17927978
Mol Cancer Ther. 2002 Aug;1(10):777-83
12492110
Methods Enzymol. 2006;407:187-94
16757324
Mol Cancer. 2008 Sep 12;7:69
18789131
Cell. 2009 Jun 26;137(7):1181-3
19563749
Science. 2004 Jun 4;304(5676):1497-500
15118125
Curr Opin Cell Biol. 2007 Apr;19(2):124-34
17314037
J Biol Chem. 2000 Aug 25;275(34):26178-86
10816576
J Biol Chem. 2005 Sep 2;280(35):31182-9
16000298
Genes Dev. 2008 Feb 15;22(4):449-62
18258752
Cancer Res. 2006 Oct 1;66(19):9601-8
17018617
Mod Pathol. 2010 Mar;23(3):392-403
20062009
J Biol Chem. 2002 Oct 11;277(41):38284-93
12161422
J Biol Chem. 2007 Apr 6;282(14):10432-40
17283074
J Biol Chem. 2006 Aug 11;281(32):22799-807
16785234
Br J Cancer. 2007 Oct 8;97(7):927-33
17848946
Clin Cancer Res. 1999 Mar;5(3):507-12
10100700
Proc Natl Acad Sci U S A. 2008 Sep 2;105(35):12791-6
18728186
J Biol Chem. 2005 Jun 24;280(25):24043-52
15840573
Mol Cell. 2008 Apr 25;30(2):203-13
18439899